期刊
BIOANALYSIS
卷 10, 期 12, 页码 889-891出版社
FUTURE SCI LTD
DOI: 10.4155/bio-2018-0127
关键词
BAV; biomarker assay validation; drug development; fit-for-purpose validation; NCI clinical trials; parallelism; regulatory considerations